How are changing the therapy options in obese diabetic type 2 patients

Česká verzia

Authors: Štěpán Svačina
Authors place of work: III. interní klinika 1. LF UK a VFN, Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in the journal: Vnitř Lék 2014; 60(10): 902-907
Category: Reviews

Summary

Classical consequence of treatment with anti-diabetic agents, including insulin, is weight gain which enhances insulin resistance and leads to a further increase in drug dose. This creates an unwanted cycle. Administration of weight neutral anti-diabetic drugs has broken this scenario. Another option is to use anti-obesity agents, but actually many of them are not available. However, in the United States, two new drugs have been used in past two years. The most important change in the treatment of obese type 2 diabetes patients is administration of anti-diabetic agents that reduce weight. These agents are well-known incretin analogs characterized by their unpleasant injecting administration. However, application becomes easier and the drugs are administered for the866 longer time period. Even greater change in treatment is administration of gliflozins. Dapagliflozin and empagliflozin enter almost simultaneously to the Czech Republic. The new class of drugs has very complex metabolic effect and in particular significantly reduces the weight even in patients treated with insulin. The treatment options have significantly expanded for obese type 2 diabetes patient in course of this year.

Key words:
anti-obesity agents – gliflozins – incretin analogs – type 2 diabetes

Zdroje

1. Svačina Š. Obezitologie a teorie metabolického syndromu. Triton: Praha 2013. ISBN 978–80–7387–678–4.

2. Svačina Š. Proč a jak působí inzulínové přípravky na hmotnost. Vnitr Lek 2014; 60(5–6): 448–453.

3. 3.Anderson JW. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage. Expert Opin Pharmacother 2007; 8(11): 1733–1742.

4. Brashier DB et al. Lorcaserin: A novel antiobesity drug. J Pharmacol Pharmacother 2014; 5(2): 175–178.

5. Xiong GL, Gadde KM.Combination phentermine/topiramate for obesity treatment in primary care: a review. Postgrad Med 2014; 126(2): 110–116.

6. Diamant M et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol 2014; 2(6): 464–473.

7. Ferrannini E et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014; 124(2): 499–508.

8. Roden M et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013; 1(3): 208–219.

9. Häring HU et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014; 37(6): 1650–1659.